For 15 minutes $5 and you can learn when you COVID-19

On August 26, the US Food and Drug Administration (FDA) announced the emergency use authorization (EUA) for fast COVID-19 test, the results can be produced in just 15 minutes, it was not only in the head at number of people lift the US, but also identify those that are positive in earlier so that they can isolate and limit the spread of the disease. The test device made with Abbott Laboratories and paper BinaxNOW Ag is called, it is the size of a credit card and can easily be used people need to be tested anywhere. It analyzes samples from a nasal swab and comes with an app that people their results that you can download received that could serve as evidence that some infection-free for schools, employers and other places where a larger number You could get along with people. Any doctor who has a suspected patient can COVID 19-writing based on their history of exposure or symptoms, a recipe for testing. must be evidence that collects specified by a doctor, nurse, school nurse or physician’s work, proteins produced by SARS-CoV-2, conducted after the virus-COVID 19th produced a fast display is similar to that used in pregnancy test, the self-contained test opens like a portfolio for the doctor to nasal swab with the paste of the sample. generated in the closed state, the chemical reagents in the sample scan for internal viral proteins and a single band when the double bonds of the test and, if positive, negative. Why did you focus on these proteins, the test is most effective when used on humans within a few days after infection, when the virus is active, to infect cells and churn out viral proteins. Abbott studies the tests carried out in seven locations in the United States on people with suspected COVID-19, all tested within seven days after the first symptoms. In these studies, the sensitivity of the test was 97.1%, which means that you can get 97.1% of the time with some false negative cases positive, and its specificity was 98.5%, which means that correctly identifies people without infection negative 98.5% of the time, with very low false positives. The gold standard for COVID-19 tests, such as the PCR test is known amplifies the genetic signatures of the virus itself is positive, during and even able to read and after the infection, if left traces of dead, inactive virus. The most recent data suggest that the PCR test can produce false negative results because the threshold for genetic signatures of these records is not sensitive enough at times when the level is too low virus. While slightly lower than that of PCR assay sensitivity Abbott “in sensitivity every drop compared with [Abbott] PCR testing more than for the fact that the test is repeatable,” says Joseph Petrosino, professor and chair of the Department of Molecular Virology and microbiology at Baylor college of Medicine, who have not been involved in the development or testing BinaxNOW. “If you take this test every other day or twice a week, then you can be pretty sure that something is wrong day would not have gone wrong during the second day.” Tests the same group determined by people like all students at a school or residents of a particular attention at the moment is repeatedly luxury home in quick succession, at the moment in the United States, it can help several days or even weeks for the results take over from PCR tests, and delays in curbing infection problems. Test people might be routinely used to identify and isolate those who have a positive result earlier, reducing their ability to COVID 19-proliferation This should contain significantly epidemics as open new schools and people back to work. Admiral Brett Giroir, the Secretary of Health, which oversees the country’s control efforts, wrote on Twitter that the faster delivery for the test results were a “game changer”. The costs for the Abbott test is also an advantage; for $5, it could be accessible to more people, although at the moment many insurers cover the cost of COVID-19 test. Since April, Abbott has built two new plants and ship plans BinaxNOW tens of millions trial in September in the production and scale up to produce 50 million tests per month in early October.
Photo copyright Abbott